DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 814-826

  Hascher, Antje ^a,b   Haase, Ann Kristin ^a   Hebestreit, Katja ^a   Rohde, Christian ^a   Klein, Hans Ulrich ^a   Rius, Maria ^c   Jungen, Dominik ^a   Witten, Anika ^a   Stoll, Monika ^a   Schulze, Isabell ^a   Ogawa, Seishi ^d   Wiewrodt, Rainer ^a   Tickenbrock, Lara ^b   Berdel, Wolfgang E ^a   Dugas, Martin ^a   Thoennissen, Nils H ^a   Muller Tidow, Carsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Hamm Lippstadt University of Applied Science   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BISULFITE; DNA METHYLTRANSFERASE; POLYCOMB GROUP PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL MATURATION; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; ENZYME INHIBITION; EPIGENETICS; GENE TARGETING; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC SELECTION; GENETIC VARIABILITY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRC2 GENE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BINDING SITES; CELL LINE, TUMOR; DNA METHYLATION; DNA-CYTOSINE METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PHENOTYPE; POLYCOMB-GROUP PROTEINS;

EID: 84896707487     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1483     Document Type: Article

References (42)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-92.
2. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11: 726-34.
3. Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS ONE 2011;6:e27889.
4. Gore SD. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005;2 Suppl 1: S30-5.
5. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the GermanMDSStudy Group. J Clin Oncol 2011;29:1987-96.
6. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21:430-46.
7. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 2012;72: 1170-81.
8. Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013;754:253-83.
9. Shats I, Gatza ML, Chang JT, Mori S,WangJ, Rich J, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011;71:1772-80.
10. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115: 1503-21.
11. Carmona FJ, Villanueva A, Vidal A, Munoz C, Puertas S, Penin RM, et al. Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol 2012;228:230-40.
12. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, et al. Adjuvant therapy with small hairpin RNA interference prevents nonsmall cell lung cancer metastasis development in mice. Cancer Res 2008;68:1896-904.
13. Yu J, Bulk E, Ji P, Hascher A, Tang M, Metzger R, et al. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res 2010;16:2275-83.
14. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res 2009;15:22-9.
15. Bisping G, Wenning D, Kropff M, Gustavus D,Müller-Tidow C, Stelljes M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009;15:520-31.
16. Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwable J, et al. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther 2006;5:3105-12.
17. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008;454:766-70.
18. Schoofs T, Rohde C, Hebestreit K, Klein HU, Gollner S, Schulze I, et al. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood 2013;121:178-87.
19. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, et al. Base-pair resolution DNAmethylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 2012;8:e1002781.
20. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, et al. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res 2010;38:D620-5.
21. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125:301-13.
22. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, et al.DNAbinding factors shape the mouse methylome at distal regulatory regions. Nature 2011;480:490-5.
23. Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, et al. The accessible chromatin landscape of the human genome. Nature 2012;489:75-82.
24. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
25. Nguyen DX. Tracing the origins of metastasis. J Pathol 2011;223: 195-204.
26. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
27. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007;14:377-86.
28. Metsuyanim S, Pode-Shakked N, Schmidt-Ott KM, Keshet G, Rechavi G, Blumental D, et al. Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes. Stem Cells 2008;26:1808-17.
29. Huidobro C, Fernandez AF, Fraga MF. The role of genetics in the establishment and maintenance of the epigenome. Cell Mol Life Sci 2013;70:1543-73.
30. Ju HX, An B, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol 2011;178:1835-46.
31. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
32. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135-41.
33. Bouchard J, Momparler RL. Incorporation of 5-Aza-20-deoxycytidine-50- triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol 1983;24:109-14.
34. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7.
35. Taylor GA, Jackman AL, Calvert AH, Harrap KR. Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor CB 3717. Adv Exp Med Biol 1984;165 Pt B:379-82.
36. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011; 29:516-23.
37. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-30.
38. Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 2009;69:8127-32.
39. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42.
40. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6.
41. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39:157-8.
42. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010;20:440-6.